Multiple Myeloma: Plasma Cell Cancer — Symptoms, Diagnosis, and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Multiple myeloma (MM) is a malignant clonal plasma cell disorder characterized by bone marrow infiltration and monoclonal immunoglobulin (M-protein) production. It represents approximately 10% of hematological malignancies and 1-2% of all cancers, with approximately 35,000 new US cases annually. Median age at diagnosis is 70 years. Precursor states include MGUS (monoclonal gammopathy of undetermined significance) and smoldering myeloma. MM causes anemia, bone pain and lytic lesions, renal failure, hypercalcemia, and recurrent infections from immunosuppression. Multiple Myeloma: Plasma Cell Cancer — Symptoms, Diagnosis, and Treatment is a medical condition that affects patients across various age groups and demographics. It requires proper medical attention and management. This page provides evidence-based information about Multiple Myeloma: Plasma Cell Cancer — Symptoms, Diagnosis, and Treatment to help patients understand the condition, its causes, symptoms, and available treatment options.

The etiology of MM is incompletely understood. MGUS progresses to MM at a rate of approximately 1% per year. Black Americans have a 2-3 times higher incidence of MM than White Americans, and typically present at a younger age. Obesity, radiation exposure, and agricultural chemical exposure are associated with slightly elevated risk. Hereditary factors include germline variants in MYC, CCND1, and HGF pathways. Genomic landscape of MM involves initiating events (IgH translocations, hyperdiploidy) and acquired secondary events (RAS mutations, TP53 deletion, MYC rearrangement, del17p, gain 1q21) that drive progression. The causes of Multiple Myeloma: Plasma Cell Cancer — Symptoms, Diagnosis, and Treatment are often multifactorial, involving a combination of genetic predisposition, environmental exposures, and lifestyle factors. In some cases, infectious agents, immune dysfunction, or metabolic imbalances may contribute. Risk factors vary but may include age, sex, family history, and pre-existing medical conditions. Understanding the causes guides prevention strategies and informs treatment choices.

CRAB manifestations define symptomatic MM requiring treatment: hyperCalcemia (nausea, confusion, polyuria), Renal insufficiency (elevated creatinine, cast nephropathy from free light chains), Anemia (fatigue, pallor, dyspnea from marrow suppression), and Bone lesions (severe, persistent bone pain particularly in the spine and ribs, pathological fractures, vertebral compression fractures with back pain). Recurrent bacterial infections from hypogammaglobulinemia (pneumonia, sinusitis). Hyperviscosity syndrome (visual changes, headache, bleeding) from very high M-protein levels. Peripheral neuropathy from AL amyloidosis complication. Symptoms of Multiple Myeloma: Plasma Cell Cancer — Symptoms, Diagnosis, and Treatment can range from mild to severe and may develop gradually or appear suddenly. Common presentations include pain, inflammation, or functional impairment related to the affected system. Symptoms may fluctuate over time with periods of remission and exacerbation. Consult a healthcare provider if symptoms persist or worsen, as early diagnosis improves outcomes.

Diagnosis requires bone marrow biopsy (greater than or equal to 10% clonal plasma cells) plus any CRAB criterion or IMWG biomarker of malignancy, or biopsy-proven plasmacytoma. Serum and urine protein electrophoresis with immunofixation identify M-protein type. Serum free light chain (FLC) assay detects non-secretory or oligosecretory disease. FISH panel identifies high-risk cytogenetics: del(17p), t(4;14), t(14;16), t(14;20), gain 1q21. PET-CT or whole-body MRI for skeletal staging. Revised ISS (R-ISS) integrates ISS stage, LDH, and FISH cytogenetics for prognosis. MRD negativity by flow cytometry or NGS (sequencing sensitivity less than 10^-5 or 10^-6) is the new treatment response standard. Diagnosis of Multiple Myeloma: Plasma Cell Cancer — Symptoms, Diagnosis, and Treatment typically involves a thorough clinical history, physical examination, and targeted investigations. Laboratory tests, imaging studies, or specialist referrals may be required to confirm the diagnosis. Accurate diagnosis is essential for appropriate management and prevents unnecessary treatment.

Transplant-eligible newly diagnosed MM: Dara-VRd (daratumumab plus bortezomib plus lenalidomide plus dexamethasone) for 4-6 cycles, stem cell mobilization, high-dose melphalan plus auto-SCT, consolidation, then lenalidomide maintenance. Transplant-ineligible: Dara-Rd (MAIA regimen) or VRd-lite. Relapsed/refractory MM: Dara-Pd (daratumumab plus pomalidomide plus dexamethasone), carfilzomib-based regimens, isatuximab combinations. Fourth-line or later: ide-cel or cilta-cel CAR-T; belantamab mafodotin (BCMA-ADC); selinexor; bispecific antibodies (teclistamab, talquetamab). Bone disease: zoledronic acid or denosumab; vertebroplasty or kyphoplasty for vertebral fracture. Treatment of Multiple Myeloma: Plasma Cell Cancer — Symptoms, Diagnosis, and Treatment is tailored to the individual and depends on severity and underlying cause. Options may include medications, lifestyle modifications, surgical interventions, or supportive therapies. Multidisciplinary care is often recommended for complex cases. The goal is to alleviate symptoms, slow disease progression, and improve quality of life.

MM remains incurable with conventional therapy but has become a chronic condition with modern treatments. Median OS with modern quadruplet therapy exceeds 6-8+ years for standard-risk disease. R-ISS I 5-year OS approximately 80%; R-ISS III approximately 40%. High-risk cytogenetics (del17p, t(4;14), t(14;16), gain 1q21, complex karyotype) confer median OS of 2-3 years despite aggressive therapy. Achievement of MRD negativity (greater than or equal to 10^-5 sensitivity) is strongly associated with longer PFS and OS across all cytogenetic risk groups. CAR-T cell therapy shows unprecedented response rates in heavily pre-treated patients. The prognosis for Multiple Myeloma: Plasma Cell Cancer — Symptoms, Diagnosis, and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.

MGUS patients require periodic monitoring (annually for low-risk, every 3-6 months for high-risk) to detect early myeloma progression. Annual serum protein electrophoresis (SPEP) plus serum FLC ratio is the standard monitoring approach for MGUS. The PREVENT trial and other studies are investigating whether treatment of high-risk smoldering myeloma (greater than or equal to 20% plasma cells plus M-protein greater than 2 g/dL plus elevated FLC ratio) can prevent or delay progression to symptomatic MM. Obesity management may reduce risk of progression. No general population screening is currently recommended.

Go to the ER immediately for acute severe back pain with new limb weakness or urinary incontinence from vertebral compression fracture causing spinal cord compression (oncological emergency); acute confusion or polyuria from severe hypercalcaemia; oliguria with rapidly rising creatinine from myeloma cast nephropathy; or sepsis from profound immunosuppression. See a haematologist urgently for unexplained anaemia with elevated total protein or globulin on routine bloods; recurrent bacterial infections; new unexplained bone or rib pain; proteinuria or new renal impairment; or an M-protein detected on protein electrophoresis. Routine: all MGUS patients require annual serum protein electrophoresis and free light chain ratio surveillance. Black Americans with a family history of myeloma are at higher risk and should have a low threshold for haematology referral.